Finance

Lists
Why is GH up २.५०%?
Dive Deeper
GH:NASDAQ
Guardant Health Inc
US$ १६६.६६
+२.५०%
(+४.०७) 1D
US$ १६६.६६
०.००% (०.००)
After hours
Closed: अक्टोबर २१, १६:००:०१ GMT-४  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for GH...
Open
US$ १६२.२९
High
US$ १७१.२२
Low
US$ १६२.००
Mkt. cap
२२.३७ अरब
Avg. vol.
१७.७८ लाख
Volume
०.००
52-wk high
US$ १९१.०१
52-wk low
US$ ६६.५९
EPS
-US$ ३.५०
Beta
१.५८
Shares outstanding
१३.४२ करोड
No. of employees
२ हजार
Open
US$ १६२.२९
High
US$ १७१.२२
Low
US$ १६२.००
Mkt. cap
२२.३७ अरब
Avg. vol.
१७.७८ लाख
Volume
०.००
52-wk high
US$ १९१.०१
52-wk low
US$ ६६.५९
EPS
-US$ ३.५०
Beta
१.५८
Shares outstanding
१३.४२ करोड
No. of employees
२ हजार
News stories
From web sources and news partners
Profile
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers. Wikipedia
About Guardant Health Inc
CEOHelmy Eltoukhy | AmirAli Talasaz
Employees२.५ हजार
Founded२०१२
HeadquartersPalo Alto, क्यालिफोर्निया, संयुक्त राज्य अमेरिका
Sector-
Websiteguardanthealth.com
Analyst ratings
Based on 19 analysts giving stock ratings to GH in the past 3 months
Strong buy
Buy
19
Hold
0
Sell
0
12-month forecast
Based on 19 Wall Street analysts offering 12 month price targets for GH in the last 3 months.
Highest
Current US$ १६६.६६
US$ २२५.०० (+३५.०१%)
Average
US$ २०३.२९ (+२१.९८%)
Lowest
US$ १८०.०० (+८.००%)
Analyst
Recommendation
Action
Price target
Projected
Date
Kallum Titchmarsh
Morgan Stanley
Buy
Maintained
US$ २००.००
+२०%
10/20/2026
Eve Burstein
Bernstein
Buy
Reiterated
US$ २१०.००
+२६%
10/19/2026
Casey Woodring
J.P. Morgan
Buy
Maintained
US$ १९५.००
+१७%
10/14/2026
Lu Li
Bank of America Securities
Buy
Maintained
US$ २००.००
+२०%
10/09/2026
Michael Ryskin
Bank of America Securities
Buy
Maintained
US$ २००.००
+२०%
10/09/2026
Luke Sergott
Barclays
Buy
Maintained
US$ २२०.००
+३२%
10/07/2026
Subbu Nambi
Guggenheim
Buy
Maintained
US$ २००.००
+२०%
10/01/2026
Evie Koslosky
Goldman Sachs
Buy
Maintained
US$ २२५.००
+३५%
09/20/2026
William Bonello
Craig-Hallum
Buy
Maintained
-
-
09/15/2026
David Westenberg
Piper Sandler
Buy
Maintained
US$ १९३.००
+१५.८%
09/15/2026
Unknown Analyst
UBS
Buy
Maintained
US$ २२५.००
+३५%
09/09/2026
Doug Schenkel
UBS
Buy
Maintained
US$ २२५.००
+३५%
09/09/2026
Jamie Clark
Rothschild & Co Redburn
Buy
Initiated
US$ २०३.००
+२१.८%
09/08/2026
Matt Larew
William Blair
Buy
Maintained
-
-
09/08/2026
Mark Massaro
BTIG
Buy
Reiterated
US$ १९५.००
+१७%
09/01/2026
Bradley Bowers
Mizuho Securities
Buy
Maintained
US$ २००.००
+२०%
08/04/2026
Mason Carrico
Stephens
Buy
Maintained
US$ १९५.००
+१७%
08/04/2026
Kyle Mikson CFA
Canaccord Genuity
Buy
Maintained
US$ २०५.००
+२३%
08/02/2026
Daniel Arias
Stifel Nicolaus
Buy
Maintained
US$ १८०.००
+८%
08/03/2026
Dan Leonard
RBC Capital
Buy
Reiterated
US$ २००.००
+२०%
07/31/2026
Daniel Brennan
TD Cowen
Buy
Reiterated
US$ २१०.००
+२६%
07/31/2026
Brandon Couillard
Wells Fargo
Buy
Maintained
US$ १२५.००
-२५%
07/29/2026
Patrick B Donnelly
Citi
Buy
Maintained
US$ २१५.००
+२९%
07/08/2026
Vijay Kumar
Evercore ISI
Buy
Maintained
US$ २००.००
+२०%
07/06/2026
Puneet Souda
Leerink Partners
Buy
Reiterated
-
-
06/02/2026
Paige Chamberlain‏
Wolfe Research
Buy
Reiterated
US$ १५०.००
-१०%
06/01/2026
Unknown Analyst
Wolfe Research
Buy
Reiterated
US$ १५०.००
-१०%
06/01/2026
Andrew Brackmann
William Blair
Buy
Maintained
-
-
05/27/2026
Catherine Ramsey Schulte
Robert W. Baird
Buy
Maintained
US$ १२९.००
-२२.६%
05/08/2026
Andrew Cooper
Raymond James
Buy
Reiterated
US$ १२९.००
-२२.६%
02/23/2026
Last report
२०२६ जुलाई ३०
Fiscal period
Q2 2026
-US$ ०.४२ / -US$ ०.३९
-७.८१%miss
Revenue / Est. (USD)
३३.५० करोड / ३१.४४ करोड
+६.५३%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
Revenue
२६.५२ करोड
२८.१३ करोड
३०.१७ करोड
३३.५० करोड
Cost of goods sold
९.३६ करोड
९.९५ करोड
१०.४९ करोड
११.५९ करोड
Cost of revenue
९.३६ करोड
९.९५ करोड
१०.४९ करोड
११.५९ करोड
Research and development expenses
९.०० करोड
९.८३ करोड
९.१० करोड
९.६५ करोड
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
१८.०५ करोड
२०.४२ करोड
२२.७१ करोड
२५.०६ करोड
Operating expense
२७.०५ करोड
३०.२५ करोड
३१.८१ करोड
३४.७१ करोड
Total operating expenses
३६.४१ करोड
४०.२० करोड
४२.३० करोड
४६.३१ करोड
Operating income
-९.८९ करोड
-१२.०७ करोड
-१२.१४ करोड
-१२.८१ करोड
Other non operating income
-४८.०० हजार
-४६.८६ लाख
१५.५० लाख
३.०८ लाख
EBT including unusual items
-९.२६ करोड
-१३.०२ करोड
-११.१७ करोड
-१२.०० करोड
EBT excluding unusual items
-९.२५ करोड
-११.६५ करोड
-११.१७ करोड
-११.९० करोड
Income tax expense
१.३६ लाख
-१७.२७ लाख
३.७२ लाख
१.८५ लाख
Effective tax rate
-०.१५%
१.३३%
-०.३३%
-०.१५%
Other operating expenses
-
-
-
-
Net income
-९.२७ करोड
-१२.८५ करोड
-११.२१ करोड
-१२.०१ करोड
Net profit margin
-३४.९६%
-४५.६८%
-३७.१५%
-३५.८७%
Earnings per share
-०.३९
-०.५०
-०.४५
-०.४२
Interest and investment income
७३.९१ लाख
१.०० करोड
१.१२ करोड
१.०२ करोड
Interest expense
-९.४३ लाख
-११.८० लाख
-३०.५४ लाख
-१३.४६ लाख
Net interest expenses
६४.४८ लाख
८८.५२ लाख
८०.९७ लाख
८८.५३ लाख
Depreciation and amortization charges
-
-
-
-
EBITDA
-८.९५ करोड
-११.०६ करोड
-११.१९ करोड
-११.८६ करोड
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google एपहरू